Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: Results from a large pharmacy prescriptions database

Digestive Diseases and Sciences

Volumn 56, Issue 12, 2011, Pages 3463-3470

  Kane, Sunanda V ^a   Sumner, Michael ^b   Solomon, Dory ^b   Jenkins, Matthew ^b  

^a MAYO CLINIC   (United States)

^b SHIRE   (United States)

Author keywords

5 aminosalicylic acid; Mesalamine; Mesalazine; Persistency; Pharmacy database; Ulcerative colitis

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PRESCRIPTION DRUG;

ADULT; ARTICLE; DRUG DOSE COMPARISON; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; ADOLESCENT; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; INFANT; MIDDLE AGED; NEWBORN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRESCHOOL CHILD; STATISTICS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856186464     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1877-6     Document Type: Article

References (40)

1. Lichtenstein GR, Rutgeerts P. The importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;16:338-346.
2. Rutgeerts P, Vermeire S, Van AG. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455. (Pubitemid 46580492)
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1-V16. (Pubitemid 39120096)
4. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
5. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 2008;28:663-673.
6. Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;24:465-474. (Pubitemid 44051322)
7. Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005;57: 281-302. (Pubitemid 39536103)
8. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43. (Pubitemid 36126514)
9. Kane S, De Vos M, Riley S, Frieri G, Mittmann U. Compliance issues in inflammatory bowel disease. Rev Gastroenterol Disord. 2005;5:101-106.
10. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53: 1020-1024. (Pubitemid 351379831)
11. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544. (Pubitemid 36875345)
12. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198. (Pubitemid 36951655)
13. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-336. (Pubitemid 12098750)
14. Bernal I, Domenech E, Garcia-Planella E, et al. Medicationtaking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165-2169.
15. Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13:1244-1249. (Pubitemid 47597771)
16. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933. (Pubitemid 32959535)
17. Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs. 2008;68:2601-2609.
18. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol. 2003;15: 1275-1280. (Pubitemid 39049669)
19. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14:s2-s12. (Pubitemid 351276789)
20. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:1190-1196. (Pubitemid 44633590)
21. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119:S12-S17.
22. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76-87. (Pubitemid 350294021)
23. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101: 1398-1405. (Pubitemid 46832237)
24. Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther. 2009;31:644-656.
25. Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007;41:1812-1818. (Pubitemid 350044343)
26. Lee PP, Walt JG, Chiang TH, Guckian A, Keener J. A gap analysis approach to assess patient persistence with glaucoma medication. Am J Ophthalmol. 2007;144:520-524. (Pubitemid 47429624)
27. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107-1113. (Pubitemid 44847467)
28. Rubin DT, Siegel CA, Kane SV, et al. The impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009;15:581-588.
29. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1-10.
30. Magowan SKS, Lange J. 5-ASA prescription refill rates of ulcerative colitis are independent of formulation and dosing regimens. Am J Gastroenterol. 2006;101:S447. (Abstract 1144).
31. Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther. 2009;29:1114-1120.
32. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29:855-862.
33. Collinson S. Payment for treatment adherence: incentives help vulnerable patients to stay well. BMJ. 2007;335:317. (Pubitemid 47310856)
34. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-550. (Pubitemid 46513223)
35. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009;137:502-511.
36. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol. 1999;94:1733-1742. (Pubitemid 29315874)
37. Nguyen GC, Laveist TA, Harris ML, Datta LW, Bayless TM, Brant SR. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1233-1239.
38. DiMatteo MR, Sherbourne CD, Hays RD, et al. Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol. 1993;12:93-102.
39. D'Inca R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166-172. (Pubitemid 350256604)
40. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.